GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc announced that the FDA approved Jemperli (dostarlimab) under the accelerated approval pathway for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer, making it the first and only immunotherapy approved for this group. In AZUR-1, investigator-assessed results showed sustained clinical complete responses at 12 months in 68% of evaluable patients (98/144; 95% CI: 60%–76%). An exploratory analysis found 76% (110/144; 95% CI: 69%–83%) had no evidence of cancer one year or more after treatment; no recurrences have been reported among responders after median follow-up of more than two years.
Jemperli monotherapy could help eligible patients avoid chemotherapy, radiation and surgery. Serious adverse reactions occurred in 20% of patients, and adverse reactions led to permanent discontinuation in 3%; the most common reactions were fatigue (32%), rash (22%), diarrhoea (18%) and pruritus (17%).
GSK plc reported global phase Ib dose-optimisation results for its investigational B7-H3-targeted antibody-drug conjugate risvutatug rezetecan (Ris-Rez) in relapsed extensive-stage small cell lung cancer. Among evaluable patients, confirmed objective response rate was 61% at 8 mg/kg (11 of 18; 95% CI: 35.7% to 82.7%) and 32% at 6 mg/kg (7 of 22; 95% CI: 13.9% to 54.9%). GSK said the results, together with data from Hansoh’s phase III ARTEMIS-008 study in SCLC, supported selection of 8 mg/kg for its global phase III EMBOLD SCLC-301 study.
At a median follow-up of 100.5 days, grade 3 or higher treatment-related adverse events were reported in 42% of patients at 8 mg/kg and 15% at 6 mg/kg; haematological events were most common. Interstitial lung disease occurred in 1 of 50 patients (2%) and was grade 2. The analysis included 50 patients who had received a median of two prior therapies. Enrollment in the dose-optimisation portion was ongoing at data cut-off, and longer follow-up will be needed to further characterise response durability. The results will be presented at ESMO Congress 2026.
GSK plc reports that James Ford, SVP and Group General Counsel, Legal and Compliance, acquired 326.441 ADS; Maya Martinez-Davis, President, acquired 351.842 ADS; and Shobie Ramakrishnan, Chief Digital and Technology Officer, acquired 724.875 ADS. Each acquisition was priced at $46.9482 per ADS on October 13, 2026, following reinvestment of dividends paid to shareholders on October 8, 2026. The transactions took place on the New York Stock Exchange.
GSK plc reported dividend reinvestment-related increases in executives’ notional interests on October 12, 2026, following dividends paid to shareholders on October 8, 2026. Under the Deferred Annual Bonus Plan, Chief Executive Officer Luke Miels had an increase of 1,413 ordinary shares; Chief Financial Officer Julie Brown, 1,863; SVP and Group General Counsel, Legal and Compliance James Ford, 783; President, Corporate Development David Redfern, 894; President, Global Supply Chain Regis Simard, 1,103; President, Global Affairs Philip Thomson, 660; CEO, ViiV Healthcare and President, Global Health, GSK Deborah Waterhouse, 987; and Chief Scientific Officer Tony Wood, 1,157. Each was priced at £17.3550. Chief Digital and Technology Officer Shobie Ramakrishnan had a notional-interest increase of 364 ADS at $46.5400. Separately, President Maya Martinez-Davis acquired 179.308 ADS at $46.5400, and Brown acquired 2,409.639 ordinary shares at £17.3550 under the Performance Share Plan, subject to a 2-year holding period.
GSK plc reported dividend-reinvestment acquisitions of ordinary shares and American Depositary Shares by people identified as persons discharging managerial responsibilities or persons closely associated with them.
Ordinary-share transactions were reported at £17.5904 on October 8, 2026, following dividends paid that day. American Depositary Share transactions were reported at $46.5883 on October 9, 2026, following dividends paid on October 8. The ordinary-share transactions list the London Stock Exchange, while the ADS transactions list the New York Stock Exchange.
GSK plc reported acquisitions by its officers and associated persons. On October 8, Chief Executive Officer Luke Miels (3 ordinary shares), President, Europe Lynn Baxter (39), SVP and Group General Counsel, Legal and Compliance James Ford (13), President, Corporate Development David Redfern (80), President, Global Supply Chain Regis Simard (32), President, Global Affairs Philip Thomson (52), CEO, ViiV Healthcare and President, Global Health, GSK Deborah Waterhouse (66), SVP & Company Secretary Victoria Whyte (62), and Neil Falkingham, PCA of Lynn Baxter (64), acquired ordinary shares through dividend reinvestment at £17.5852 per share.
Also on October 8, Victoria Whyte acquired 243 ordinary shares and Iain Whyte, PCA of Victoria Whyte, 1,182, following dividend reinvestment at £17.5904. President Maya Martinez-Davis acquired 10.155 ADS at $47.0200 in her GSK Executive Supplemental Savings Plan account on October 7. On October 9, Chief Financial Officer Julie Brown acquired 14 ordinary shares under GSK’s Share Reward Plan at £17.6539, comprising 7 partnership and 7 matching shares; other participants reported the same terms. Further transactions that day included dividend reinvestments and ISA-held shares at £17.6650.
GSK plc announced that Wendy Becker, an independent Non-Executive Director of GSK, has been appointed as a Non-Executive Director of Tesco PLC, effective November 1, 2026.
GSK plc notified the market that 19,352 ordinary shares of 31¼ pence each were admitted to trading under existing block listing admissions connected with its Share Save Plan 2022. The admission covered August 7, 2026, through October 2, 2026, on the London Stock Exchange Main Market. The total number of securities admitted to trading following admission was 4,316,311,662, and the shares are fully fungible with existing ordinary shares.
GSK plc reported that its issued share capital consisted of 4,316,311,549 Ordinary Shares as of September 30, 2026, including 270,881,064 shares held in Treasury. Total voting rights were 4,045,430,485, which shareholders may use as the denominator for determining whether they must notify the company of an interest or a change in an interest.
GSK plc reported that its President, Maya Martinez-Davis, acquired 9.414 notional American Depositary Shares (ADS) within her GSK Executive Supplemental Savings Plan account. The transaction was listed at a price of $50.7200 on September 22, 2026, with the New York Stock Exchange shown as the place of transaction.